NCT05642793

Effect of Postvitrectomy Proactive Use of Conbercept on Postoperative Complications in PDR Patients

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Peking University Third Hospital · Academic / Other
• Sex: All
• Age: 19 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is an unmasking randomized clinical trial. the main purpose of this study is to analyze whether posvitrectomy proactive use of conbercept can reduce the rate of postoperative complication in PDR patients.

Conditions

• Proliferative Diabetic Retinopathy

Interventions

Type	Name	Description
DRUG	proactive Anti-VEGF (conbercept) use	preventive intravitreal injection of conbercept 2 weeks after vitrectomy, and repeat at 5 weeks and 8 weeks if either of the following is present: intravitreal VEGF concentration at 2 weeks postop is higher than 100 pg/ml, or clinical presentation of DME, VH or NVG.
DRUG	passive Anti-VEGF (conbercept) use	No intravitreal injection of conbercept is used until the patient present with postoperative DME, VH, NVG

Timeline

• Start date: 2022-04-01
• Primary completion: 2023-09-30
• Completion: 2024-03-01
• First posted: 2022-12-08
• Last updated: 2022-12-14

Locations

1 site across 1 country: China